These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 19098390)

  • 21. Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.
    Cho JR; Rollini F; Franchi F; Ferrante E; Angiolillo DJ
    Vasc Health Risk Manag; 2014; 10():177-88. PubMed ID: 24729713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
    Arif SA; D'Souza J; Gil M; Gim S
    Am J Health Syst Pharm; 2015 Oct; 72(19):1615-22. PubMed ID: 26386102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?
    Duerschmied D; Bode C
    Hamostaseologie; 2012; 32(3):221-7. PubMed ID: 22777302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vorapaxar for the reduction of atherothrombotic events.
    Diaz-Ricart M; Escolar G
    Drugs Today (Barc); 2014 Nov; 50(11):747-56. PubMed ID: 25525635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of vorapaxar for the prevention of atherothrombotic events.
    Wang A
    Expert Opin Pharmacother; 2015; 16(16):2509-22. PubMed ID: 26480240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SCH 530348: a novel oral thrombin receptor antagonist.
    Bonaca MP; Morrow DA
    Future Cardiol; 2009 Sep; 5(5):435-42. PubMed ID: 19715408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555.
    Leonardi S; Tricoci P; Becker RC
    Drugs; 2010 Oct; 70(14):1771-83. PubMed ID: 20836572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials.
    Capodanno D; Bhatt DL; Goto S; O'Donoghue ML; Moliterno DJ; Tamburino C; Angiolillo DJ
    J Thromb Haemost; 2012 Oct; 10(10):2006-15. PubMed ID: 22845871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel anti-platelet agents: focus on thrombin receptor antagonists.
    de Souza Brito F; Tricoci P
    J Cardiovasc Transl Res; 2013 Jun; 6(3):415-24. PubMed ID: 23435863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis.
    Al-Khafaji K; Mutyala M; Al-Khafaji N; Harper Y; Ismail I; Hakim H; Arora RR
    Am J Ther; 2017; 24(6):e730-e736. PubMed ID: 26398717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist.
    Cai TQ; Wickham LA; Sitko G; Michener MS; Raubertas R; Handt L; Chintala M; Seiffert D; Forrest M
    Eur J Pharmacol; 2015 Jul; 758():107-14. PubMed ID: 25857224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke.
    Shinohara Y; Goto S; Doi M; Jensen P
    J Stroke Cerebrovasc Dis; 2012 May; 21(4):318-24. PubMed ID: 20947374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiplatelet therapy for atherothrombotic disease: how can we improve the outcomes?
    Moser M; Bode C
    J Thromb Thrombolysis; 2010 Aug; 30(2):240-9. PubMed ID: 20467788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.
    Cheng JW
    Vasc Health Risk Manag; 2016; 12():263-8. PubMed ID: 27366081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vorapaxar in the secondary prevention of atherothrombotic events.
    Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
    N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet protease-activated receptor antagonism in cardiovascular medicine.
    Wiisanen ME; Moliterno DJ
    Coron Artery Dis; 2012 Sep; 23(6):375-9. PubMed ID: 22781741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.
    TRA*CER Executive and Steering Committees
    Am Heart J; 2009 Sep; 158(3):327-334.e4. PubMed ID: 19699853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome.
    Leonardi S; Tricoci P; Becker RC
    Adv Cardiol; 2012; 47():87-99. PubMed ID: 22906905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease.
    Gryka RJ; Buckley LF; Anderson SM
    Drugs R D; 2017 Mar; 17(1):65-72. PubMed ID: 28063023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis.
    Leonardi S; Becker RC
    Handb Exp Pharmacol; 2012; (210):239-60. PubMed ID: 22918734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.